 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 16, 2021 GLOBE NEWSWIRE -- ORIC Pharmaceuticals, Inc. Nasdaq: ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of 25-year industry veteran Steven L. Hoerter to its Board of Directors. 